In the United States, approximately 30% of total health care costs for an individual are incurred in the last year of life (Earle and Schrag, 2008) . Terminal cancer patients with metastatic disease are treated with expensive "targeted" therapies, often costing tens of thousands of dollars with minimal survival benefit. If we take the cost and clinical benefit of the epidermal growth factor receptor (EGFR) targeting drug cetuximab in lung cancer as a standard, it would cost $440 billion to extend by one year the life of all Americans who die of cancer annually (Fojo and Grady, 2009 ). In the past, the pharmaceutical industry has predominantly been focused on the development of ever newer and better cancer drugs, without paying sufficient attention to the identification of the (often small) fraction of patients that respond to their drugs. It will require a disruptive innovation, a radically new approach to the way we diagnose and treat cancer, to stem the spiraling cost of care for cancer patients. A critical aspect of this more individualized approach to cancer therapy will be the development of biological indicators (biomarkers) that help identify those patients that are most likely to respond to these expensive therapies.
The Need for Biomarkers
We now understand why it is so hard to win the war on cancer. Cancer results from the sequential acquisition of a number of genetic alterations, and these mutations are often distinct in tumors that appear very similar when examined through conventional diagnostics. This molecular heterogeneity represents a major obstacle to the effective treatment of cancer and requires the development of new classes of biomarkers to separate these apparently similar tumors into distinct subgroups that differ in response to therapy. There are three types of clinically relevant biomarkers: prognostic biomarkers (that predict disease outcome without further treatment), predictive biomarkers (that foretell response to a specific therapy), and pharmacodynamic biomarkers (that help decide on the optimal dose of a drug for an individual patient). A biomarker can be both prognostic and predictive, a good example being the estrogen receptor in breast cancer. Estrogen receptorpositive tumors have in general a more favorable outcome and are more often responsive to hormonal therapy. Moreover, if a biomarker identifies one group of patients having negligible risk of disease recurrence and a second group that has almost all of the risk of disease progression, obviously the latter group will also receive nearly all of the benefits of additional (adjuvant) therapy, yielding a combined prognostic/predictive biomarker.
There are only a few clinically useful biomarkers that predict the response of a cancer to conventional chemotherapy. However, it is likely that this is very different for biomarkers of response to the newer classes of "targeted therapeutics"-drugs that specifically act on signaling pathways that are active in the cancer cell or the surrounding stroma. For instance, the analysis of cancer genotypes by selected sequencing of cancer genomes has identified strong correlations between the presence of the oncogenic BCR-ABL translocation in leukemia and responses to the drug imatinib mesylate (see Review by A.
Nussenzweig and M.C. Nussenzweig on page 27 of this issue). Similarly, the presence of mutations in EGFR is correlated with responses to small-molecule inhibitors of its activity. For a list of associations between genotypes and responses to kinase-inhibitory drugs, see Janne et al. (2009) and Sawyers (2008) . Many of these relationships between genetic alterations and responses to drugs can be explained by "oncogene addiction"-an acquired dependency of tumors on persistent signaling through a given activated signaling pathway-as sudden inhibition of this signaling by drug treatment can cause cell death (Weinstein and Joe, 2006) . Such correlations between genotype and drug response are especially straightforward to identify when the mutant allele is either a direct target of the drug or a component of the signaling pathway targeted by the drug. A variety of methods are readily available for identifying structural alterations in genes of major signaling pathways, including next generation sequencing and comparative genomic hybridization (Pinkel and Albertson, 2005; Stratton et al., 2009 ). Biomarker discovery becomes challenging when there are no likely suspects to consider. This is the case for antiangiogenic drugs, like bevacizumab, or for "multikinase" inhibitory drugs, like dasatinib, sorafenib, and sunitinib, for which it is often not clear which of the multiple targets is primarily responsible for their anticancer effects.
Tissue Is an Issue
Biomarkers of drug responsiveness are most readily discovered through analysis of the tumor itself. There are at least three major obstacles in the discovery of Hoshida et al., 2008) . A second problem is that most early stage (phase II) clinical trials, in which biomarkers are typically discovered, enroll patients with metastatic disease. This often limits access to tumor tissue through biopsies due to the anatomical locations of the metastases. A potential solution is the use of noninvasive technologies to assess tumor biomarkers. For example, collecting circulating tumor cells can be an alternative to tissue biopsies, but the numbers of cells present in the circulation is often very small (Pantel et al., 2009 ). Alternatively, tumor genotype can be assessed through the analysis of DNA in serum, which is shed by tumor cell lysis. The use of next generation sequencing may make it feasible to mine detailed information on copy number gains, losses, or mutations from analysis of tumor DNA in serum from cancer patients (Chiu et al., 2008; Thomas et al., 2007) .
A third major factor limiting efficient biomarker discovery is access to sufficient patient samples. An unbiased genome-wide search for association between gene expression and disease outcome requires at least 40 patients whose cancer responds to treatment and an equal number of nonresponders, as smaller sample sizes will lead to spurious associations between gene activity and disease outcome. Most phase II clinical trials do not have sufficient drug responders to allow such unbiased biomarker discovery. There are several potential solutions to this problem. First, the number of patients in the trial can be greatly increased, which is time consuming and expensive. Alternatively, one can identify drug response signatures (retroviral, lentiviral, or adenoviral) . Cells are exposed to a cancer drug and resistant cells will continue to proliferate. From drug-resistant colonies, cDNAs can be recovered, identified by sequence analysis, and retested for their ability to confer drug resistance. (B) Short-hairpin RNA (shRNA) barcode loss-of-function genetic screens. Collections of shRNA vectors are expressed polyclonally in drug-sensitive cells and subjected to drug selection. Cells harboring an shRNA vector that confers drug resistance will become enriched in the population; shRNAs that enhance the sensitivity to a cancer drug will become depleted under drug selection compared to a reference population that is not exposed to drug. Each shRNA vector contains a unique identifier sequence (the barcode), which can be recovered by polymerase chain reaction (PCR) and its abundance quantified on a dedicated DNA microarray containing the barcode sequences. shRNAs that cause drug resistance are enriched and appear red on the microarray; depleted shRNAs appear green.
by correlating drug responsiveness of a large panel of cancer cell lines with their pattern of gene expression in vitro (Neve et al., 2006) . However, it is too early to tell whether such in vitro-derived drug response signatures will have clinical utility. Finally, to minimize the chance of false associations, one can survey only a limited number of genes in the phase II clinical trial samples by preselecting candidate drug response biomarkers in appropriate preclinical models using functional genetics (see below).
Functional Genetic Screens for Biomarker Discovery
Many of the events that contribute to cancer pathogenesis are epigenetic rather than genetic. Such epigenetic modifications lead to alterations in gene expression and hence to changes in cellular behavior, including responses to cancer drugs. Important information about drug responses can therefore be gleaned from analysis of gene expression patterns in cancer (van't Veer and Bernards, 2008) . But of these genes, which are critical determinants of responsiveness to a given cancer drug? As pointed out above, unbiased discovery by full genome surveys is often not an option because the tumor samples available are insufficient. Functional genetic screens in mammalian cells help to fill this gap.
The development of efficient tools to perform functional genetic screens in mammalian cells has enabled the discovery of genes that play a critical part in specific cellular processes, including responses to cancer drugs. Genetic screens, pioneered in model organisms, provide the most unbiased approach to identify genes that act in a biological process. Two types of genetic screen can be carried out in mammalian cells today. In "gain-of-function" screens sets of genes are ectopically expressed to ask which genes, when overexpressed, can modulate a biological process (Figure 1A) . Conversely, RNA interference has enabled "loss-of-function" genetic screens in mammalian cells. In this type of screen, large sets of genes are either suppressed short term by synthetic small-interfering RNAs (siRNAs) or long term through vector-encoded shRNAs, and the effects on specific biological processes are monitored. To find biomarkers of drug responses, stable suppression of gene expression by short-hairpin RNAs (shRNAs) has the advantage that it allows the use of more physiological drug concentrations because drug responses can be monitored over longer periods of time. A particularly elegant iteration of the loss-of-function screen is the shRNA barcode screen, which enables the identification of all genes whose suppression can cause alterations in drug responsiveness in a single experiment ( Figure 1B) . Because of the very nature of the genetic screens, the relationships between responses to cancer drugs and gene expression are causal rather than correlative (as is for instance the case when microarray analyses are performed). Consequently, genes identified in genetic screens are strong candidates to foretell responses to the same drugs in the clinic.
Indeed, in several cases genetic screens have yielded drug response biomarkers that could subsequently be validated in clinical samples from patients treated with the same drug. For instance, a shRNA barcode screen identified the tumor suppressor gene PTEN as a critical determinant of resistance of breast cancer to trastuzumab, an antibody that targets human epidermal growth factor receptor 2 (HER2). Subsequent analysis of some 50 tumor samples from patients treated with trastuzumab confirmed the clinical utility of the phosphatidylinositol 3-kinase (PI3K)-PTEN pathway as a biomarker to predict trastuzumab responses in breast cancer (Berns et al., 2007) . Note that the number of tumor samples required for the initial clinical validation of this biomarker is typically available from a phase II trial. Similarly, a single-well siRNA screen targeting all known and putative kinases identified CDK10 as a gene whose suppression can confer resistance to the anti-hormonal drug tamoxifen in breast cancer cells. Here too, low CDK10 expression is associated with clinical resistance to tamoxifen (Iorns et al., 2008) . Obviously, at this point such biomarkers are only candidates, which require validation in specifically designed prospective clinical studies. A clinical trial to assess the validity of the PI3K pathway as a predictor of the trastuzumab response is currently underway (Tomasello et al., 2008) .
A relatively recent concept in the treatment of cancer is that of "synthetic lethality"-a situation in which a combination of two nonlethal mutations results in cell death (Hartwell et al., 1997) . Synthetic lethality results from the fact that the acquisition of mutations also comes at a cost for the cancer cell, as the ability to respond to specific perturbations may be affected when certain regulatory circuits have been rendered defective by mutation. Knowledge of synthetic lethal interactions can therefore provide insights into the "Achilles' heel" of a cancer cell-the spot where hitting it with a targeted drug hurts the most. Loss-of-function genetic screens represent an excellent tool to identify such synthetic lethal interactions (Kaelin, 2005) . Although most people will consider synthetic lethality to be useful to identify new classes of cancer drug targets, it can also be used to identify potential drug response biomarkers. In such chemical synthetic lethality screens, one searches for genes whose suppression increases the sensitivity of cells to a cancer drug. Perhaps the most salient example of a chemical synthetic lethal interaction, although not discovered through a genetic screen, is the exquisite sensitivity of tumors harboring a BRCA1 or BRCA2 mutation to olaparib, a small-molecule inhibitor of poly [ADP]-ribose polymerase (PARP) (Farmer et al., 2005; Fong et al., 2009 ). Knowledge of synthetic lethal interactions can also suggest powerful drug combinations if the pathway that is synthetic lethal with a drug can be inhibited by another drug. Thus, screening for genes that confer a synthetic lethal phenotype in combination with an experimental cancer drug may yield clues to the most responsive patient population.
Biomarkers of Pathway Activation
In many types of cancer, the same signaling pathway is frequently targeted by mutation, but the components of the pathway that are mutated are not always the same. For instance, in breast cancer the PI3K-PTEN pathway can be activated by amplification of HER2, mutation of PIK3CA (the catalytic subunit of phosphatidyl-inositol 3-kinase), loss of its antagonist PTEN, or mutation of AKT1, and additional mechanisms of activation of this pathway may yet exist. In colon cancer for instance, 70% of patients fail to respond to EGFR inhibitory drugs, whereas only 30%-40% of this nonresponsiveness is explained by mutation of KRAS (Amado et al., 2008) . It would therefore be beneficial to have "pathway activation biomarkers" that measure activation of a pathway, as such biomarkers do not require a compete knowledge of all the possible ways in which a pathway can become activated during oncogenesis. Such pathway activation markers can consist of phospho-specific antibodies that measure activation of a downstream component of a signaling cascade, which can be measured in high throughput using protein lysate arrays (Spurrier et al., 2008) . Alternatively, pathway activation can be monitored by measuring the transcriptional output of a signaling pathway, as activation of each pathway leads to a characteristic set of alterations in gene expression . Such pathway activation signatures may have utility to guide the choice of therapy (Lee et al., 2007; Potti et al., 2006) . A potential complication in using these pathway activation biomarkers is that they often cannot inform whether activation of the pathway results from an upstream event or from more downstream activation. The point at which a signaling pathway is activated can dramatically influence the response to a pathway-inhibitory drug. For instance, elevated levels of the ligands for EGFR predict favorable responses to EGFR antibody drugs in colon cancer, but downstream mutations in KRAS are associated with nonresponsiveness. Biomarkers of pathway activation may yield similar results in both cases (Amado et al., 2008; Khambata-Ford et al., 2007) . Nevertheless, with pathwaytargeted therapy becoming increasingly used in cancer, the need to describe tumors by the pathways that drive the oncogenic process will increase accordingly. Pathway activation biomarkers can play a crucial part in this transition.
Outlook
Historically, pharmaceutical companies have not been keen to develop biomarkers of drug responsiveness. A fear of reducing the market for their drugs by identifying a large fraction of patients that are unlikely to benefit from therapy has certainly been a factor. However, it is becoming increasingly evident that drug response biomarkers can also expand the number of eligible patients for a drug. For instance, inhibitors of the anaplastic leukemia kinase (ALK) show promise for the treatment of neuroblastomas, as these tumors can carry ALK amplifications or mutations that activate ALK. Importantly, between 3% and 13% (depending on the populations studied) of non-small cell lung cancer (NSCLC) tumors harbor an EML4-ALK translocation, and in preclinical models it is particularly this group of NSCLCs that is also exquisitely sensitive to these ALK inhibitors (Koivunen et al., 2008) . Biomarkers of drug responsiveness are therefore not only a threat but also an opportunity for drug developers. Patients only stand to benefit from biomarkers, as biomarkers enable the selection of the most effective therapy upfront, sparing them the considerable toxicity associated with the conventional "trial and error" therapy choice.
Molecular diagnostics will increasingly be used to classify tumors according to the pathways that act as drivers of the oncogenic process rather than the tissue of origin. Such molecular tumor classification schemes will therefore be very helpful in selecting the appropriate pathway inhibitor for the individual patient. Co-development of drugs together with a companion diagnostic that identifies the likely responders is the logical way forward. Such companion diagnostics are most quickly developed in neo-adjuvant clinical trials, a setting in which the drug is given prior to surgery, as drug responses are almost immediately visible. Biomarker validation will be greatly helped by a new type of clinical trial, so-called "adaptive" trials. In such trials, evidence is collected to either prove or disprove a given biomarker-driven hypothesis. Treatment regimens that show a high probability of being more effective than standard therapy will graduate from the trial with their corresponding biomarkers. Adaptive clinical trials like I-SPY2 for breast cancer will become the new paradigm for co-development of drugs and diagnostics (Barker et al., 2009 ). Given that a poor biomarker can be just as bad for the patient as a bad drug, the US Food and Drug Administration (FDA) has announced its intention to also regulate clinically used biomarkers. This will require a regulatory trajectory for biomarkers that is not too dissimilar from what is currently in place for drugs, including well-designed clinical studies and appropriate quality control. Development of well-validated biomarkers will therefore take considerable effort, and most pharma companies currently lack the relevant expertise to do this. A tripartite partnership between pharma, biotech, and academia will be required to secure a more rapid transition to a more personalized treatment based on detailed insights into the specific defects of each individual cancer.
